Stockscreener 앱 받기
2.11
1.93%
0.04
전일 마감가:
$2.07
열려 있는:
$2.07
하루 거래량:
70,628
Relative Volume:
0.47
시가총액:
$64.36M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-1.5719
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
+2.93%
1개월 성능:
-25.04%
6개월 성능:
-31.05%
1년 성능:
-54.82%
1일 변동 폭
$2.00
$2.125
1주일 범위
$1.965
$2.32
52주 변동 폭
$1.90
$5.00
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
VTGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.11 | 64.36M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan
Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL - Defense World
VTGN Stock Touches 52-Week Low at $2.21 Amid Market Challenges - Investing.com UK
VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire
Mental Disorder Treatment Market Set to Witness Significant - openPR.com
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat
Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR.com
Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World
Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise
Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat
Vistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. - GuruFocus.com
VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China - ACCESS Newswire
Vistagen to Participate in Stifel 2025 Virtual CNS Forum - Business Wire
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN
VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results - accessnewswire.com
VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 - ACCESS Newswire
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - StockTitan
VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 - ACCESS Newswire
Vistagen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates - MSN
Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
VistaGen’s Earnings Call: Progress and Challenges - TipRanks
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication (NASDAQ:VTGN) - Seeking Alpha
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlight - GuruFocus.com
VistaGen Reports Q3 2025 Financial Results and Updates - TipRanks
Vistagen Reports Q3 Earnings and Pipeline Progress - TipRanks
Vistagen advances Phase 3 SAD trials with 2025 data readout target - MSN
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - sharewise
Earnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net loss - Investing.com
Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView
VistaGen Therapeutics Inc Q3 Loss Increases, But Beats Estimates - Nasdaq
Vistagen Earnings Reveal $88.6M War Chest, Phase 2A Success Fuels Pipeline Momentum - StockTitan
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance
Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result - Yahoo Finance
Vistagen Therapeutics (VTGN) Projected to Post Earnings on Tuesday - MarketBeat
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 - Marketscreener.com
USPTO grants patent to Vistagen’s neuropathic pain treatment - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
자본화:
|
볼륨(24시간):